Drug and Disease Model Resources: A Consortium to Create Standards and Tools to Enhance Model‐Based Drug Development
Authors:
Open Access
- 20 March 2013
- journal article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 2 (3) , 1-3
Abstract
Model‐based drug development (MBDD) is accepted as a vital approach in understanding patients’ drug‐related benefit and risk by integrating quantitative information integration from diverse sources collected throughout drug development.1 This perspective introduces the activities of the Drug and Disease Model Resources (DDMoRe) consortium, founded in 2011 through the Innovative Medicines Initiative Joint Undertaking (IMI‐JU)2 as a European public–private partnership to address a lack of common tools, languages, and standards for modeling and simulation (M&S) to improve model‐based knowledge integration.CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e34; doi:10.1038/psp.2013.10; advance online publication 20 March 2013Keywords
This publication has 3 references indexed in Scilit:
- The RICORDO approach to semantic interoperability for biomedical data and models: strategy, standards and solutionsBMC Research Notes, 2011
- How to improve R&D productivity: the pharmaceutical industry's grand challengeNature Reviews Drug Discovery, 2010
- Model-based Drug DevelopmentClinical Pharmacology & Therapeutics, 2007